Citadel Advisors
VRPX

Citadel Advisors’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Citadel Advisors’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,255
Closed -$21.8K – 15793
2024
Q3 		$21.8K Buy
+1,255
New +$31.2K ﹤0.01% 12719
2023
Q1 		– Sell
-58
Closed -$9.09K – 15804
2022
Q4 		$9.09K Buy
+58
New +$13.2K ﹤0.01% 13710
2022
Q3 		– Sell
-46
Closed -$19K – 13903
2022
Q2 		$19K Buy
+46
New +$18.9K ﹤0.01% 12431
2022
Q1 		– Sell
-392
Closed -$336K – 14867
2021
Q4 		$336K Buy
+392
New +$404K ﹤0.01% 10676

Other funds holding VRPX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VWM
Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return

Citadel Advisors's VRPX Position: Q4 2024 in Review

Citadel Advisors sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q4 2024, closing a stake of 1,255 shares — an estimated $21.8K sold.

Citadel Advisors first reported a position in VRPX in Q4 2021 and held it in 4 quarters. The position peaked at $336K in Q4 2021. 11 funds tracked by Wall St. Rank hold VRPX as of Q4 2024.

  • Citadel Advisors reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,255 Virpax Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $21.8K.
  • Citadel Advisors first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Citadel Advisors's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $336K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.